{
    "clinical_study": {
        "@rank": "146364", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose Collagenase Clostridium Histolyticum", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Medium Dose Collagenase Clostridium Histolyticum", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High Dose Collagenase Clostridium Histolyticum", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of\n      edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women."
        }, 
        "brief_title": "A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Edematous Fibrosclerotic Panniculopathy (EFP)", 
        "condition_browse": {
            "mesh_term": "Edema"
        }, 
        "detailed_description": {
            "textblock": "The Phase 2a study is a randomized, double-blind multiple-dose study that is expected to\n      enroll approximately 144 women between the ages of 18 and 45 in the United States.\n      Treatment effectiveness will be evaluated by investigator and patient assessments, as well\n      as 3-D photographic imaging techniques.  Once the safety and local tolerability profile from\n      the first stage has been found to be acceptable subjects will be enrolled in stage 2.  After\n      an interim safety and local tolerability review was completed of all subjects in stage 1, it\n      was determined that enrollment in stage 2 is acceptable and has been initiated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Be a female between 18 to 45 years of age.\n\n          2. Have at least one well defined dimple that is at least 1 cm but not more than 2 cm\n             along the long axis and that is evident when the subject is standing\n\n          3. Have a photonumeric cellulite severity scale (CSS) score between 6 and 12\n\n          4. Have a Body Mass Index (BMI) >19  and <30 kg/m2, and intends to maintain stable body\n             weight throughout the duration of the study\n\n          5. Be willing to apply appropriate sunscreen to the selected quadrant before each\n             exposure to the sun while participating in the study\n\n          6. Be judged to be in good health, based upon the results of a medical history, physical\n             examination, and laboratory profile at screening.\n\n          7. Have a negative urine pregnancy test at screening and before injection of AA4500 and\n             be using an effective contraception method (ie, abstinence, intrauterine device\n             [IUD], hormonal [estrogen/progestin] contraceptives, or barrier control) for at least\n             one menstrual cycle prior to study enrollment and for the duration of the study.\n\n          8. Be willing and able to cooperate with the requirements of the study.\n\n          9. Voluntarily sign and date an informed consent agreement approved by the Institutional\n             Review Board/Independent Ethics Committee/Human Research Ethics Committee\n             (IRB/IEC/HREC).\n\n         10. Be able to read, complete and understand the Patient Reported Outcomes rating\n             instruments in English.\n\n        Exclusion Criteria:\n\n          1. Thyroid disease, unless controlled with medication for \u2265 6 months\n\n          2. Uncontrolled diabetes mellitus, as determined by the investigator\n\n          3. Uncontrolled hypertension, as determined by the investigator\n\n          4. Vascular disorder (eg, phlebitis or varicose veins) in area to be treated\n\n          5. Lipedema or a lymphatic disorder\n\n          6. Cushing's disease and/or use of systemic corticosteroids\n\n          7. History of lower extremity thrombosis or post-thrombosis syndrome\n\n          8. Documented autoimmune disorder such as lupus erythematosus, rheumatoid arthritis\n\n          9. Inflammation or active infection in area to be treated\n\n         10. Cutaneous alteration in area to be treated\n\n         11. Rash, eczema, psoriasis, or skin cancer in the area to be treated\n\n         12. History of keloidal scarring or abnormal wound healing\n\n         13. Coagulation disorder\n\n         14. Taking a medication for chronic anticoagulation (except for \u2264 150 mg aspirin daily)\n\n         15. Known active hepatitis A, B or C\n\n         16. Known immune deficiency disease or a positive test for human immunodeficiency virus\n             (HIV)\n\n         17. Other significant conditions including body dysmorphic disorder, which in the\n             investigator's opinion would make the subject unsuitable for enrollment in the study\n\n         18. Is menopausal defined as 12 months of amenorrhea in the absence of other biological\n             or physiological causes, as determined by the investigator\n\n         19. Has used any of the following for the treatment of EFP on the legs or buttock within\n             the timelines identified below or intends to use any of the following at any time\n             during the course of the study:\n\n               -  Liposuction on the side of the body selected for treatment during the 12-month\n                  period before injection of AA4500\n\n               -  Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment;\n                  or surgery (including subcision) within the selected treatment quadrant during\n                  the 12-month period before injection of AA4500\n\n               -  Endermologie or similar treatments within the selected treatment quadrant during\n                  the 6-months period before injection of AA4500\n\n               -  Massage therapy within the selected treatment quadrant during the 3-month period\n                  before injection of AA4500\n\n               -  Creams (eg, Celluvera\u2122, TriLastin\u00ae) to prevent or mitigate EFP within the\n                  selected treatment quadrant during the 2-week period before injection of AA4500\n\n         20. Has a tattoo located within 2 cm of the site of injection\n\n         21. Is presently nursing a baby or providing breast milk for a baby.\n\n         22. Intends to become pregnant during the study.\n\n         23. Intends to initiate an intensive sport or exercise program during the study.\n\n         24. Has received an investigational drug or treatment within 30 days before injection of\n             AA4500.\n\n         25. Has a known systemic allergy to collagenase or any other excipient of AA4500.\n\n         26. Has received any collagenase treatments within 30 days before treatment.\n\n             -"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987986", 
            "org_study_id": "AUX-CC-831"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low Dose Collagenase Clostridium Histolyticum", 
                    "Medium Dose Collagenase Clostridium Histolyticum", 
                    "High Dose Collagenase Clostridium Histolyticum"
                ], 
                "description": "injectible intervention", 
                "intervention_name": "Collagenase Clostridium Histolyticum", 
                "intervention_type": "Biological", 
                "other_name": [
                    "AA4500", 
                    "Xiaflex", 
                    "Xiapex"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "cellulite", 
            "dimple", 
            "orange peel", 
            "cottage cheese", 
            "mattress texture"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92121"
                    }, 
                    "name": "Dermatology Cosmetic Laser Medical Associates of La Jolla"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "ATS Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coral Gables", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33146"
                    }, 
                    "name": "Dermatology Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33401"
                    }, 
                    "name": "Kenneth Beer, MD PA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63090"
                    }, 
                    "name": "Mercy Health Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10075"
                    }, 
                    "name": "Sadick Research Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stony Brook", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11794"
                    }, 
                    "name": "Stony Brook University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37215"
                    }, 
                    "name": "Tennessee Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22911"
                    }, 
                    "name": "Charlottesville Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99204"
                    }, 
                    "name": "Premier Clinical Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2, Double-blind and Placebo Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy", 
        "other_outcome": [
            {
                "description": "All noted endpoints will be evaluated at Day 73", 
                "measure": "Cellulite severity scale score change/improvement in treatment quadrant", 
                "safety_issue": "Yes", 
                "time_frame": "Day 73"
            }, 
            {
                "description": "All noted endpointed will be evaluated at Day 73", 
                "measure": "Subject assessed treatment change/improvement in treatment quadrant", 
                "safety_issue": "Yes", 
                "time_frame": "Day 73"
            }, 
            {
                "description": "All noted endpoints will be evaluated at Day 73", 
                "measure": "Photo numeric variable change.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 73"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Investigator assessed aesthetic change/improvement in treatment quadrant", 
            "safety_issue": "Yes", 
            "time_frame": "Day73"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987986"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Auxilium Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Auxilium Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}